Close Menu


Ask the manufacturers of the popular antacid drug, Zantac.

Did you know that Zantac, a popular anti-heartburn medication was one the largest selling drugs in the world? It was “initially FDA-approved”; later it was sold over the counter, but the FDA in 2019 announced the first of many voluntary recalls of Ranitidine products like Zantac after it was found that Zantac consumption arguably results in an increased risk of developing numerous cancers.

N-nitrosodimethylamine (NDMA), an environmental contaminant is a typical breakdown component of Zantac’s active ingredients, Ranitidine. Ranitidine is claimed to be inherently unstable and claimed to break down into NDMA in storage, transport, and ingestion, if heat is present. Room temperature is enough.

Ranitidine combined with a diet high in nitrates result in high amounts of NDMA production.

Cancers caused by NDMA from the former leading antacid drug.
It has been reported that liver and esophageal tumors developed in animals after administration of NDMA. Later animal studies claim to have found a correlation between NDMA exposure and animals developing tumors in the stomach, intestines, colon, kidney, lungs and other organs.

The five cancers being pursued in multi-district litigation are bladder, esophageal, stomach, liver and pancreatic.

For many decades, manufacturers of products containing Ranitidine such as Zantac, made billions of dollars each year in profits. Documents acquired in discovery are said to have proved that the manufacturers of Zantac knew of the potential dangers of Ranitidine for decades, yet they failed to warn consumers, and never advised refrigeration for this over-the-counter antacid drug.

Facebook Twitter LinkedIn